Cargando…
Healthcare price transparency in North America and Europe
Healthcare price transparency is an effort to inform patient decision-making, but also to decrease prices and their variation across healthcare systems for equivalent medical services. The initiative is meaningful only for medical services that are shoppable—such as imaging examinations—for which pa...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Institute of Radiology.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607402/ https://www.ncbi.nlm.nih.gov/pubmed/37660401 http://dx.doi.org/10.1259/bjr.20230236 |
_version_ | 1785127535706636288 |
---|---|
author | Araich, Harman Tran, Julia Jung, Jinho Horný, Michal Sadigh, Gelareh |
author_facet | Araich, Harman Tran, Julia Jung, Jinho Horný, Michal Sadigh, Gelareh |
author_sort | Araich, Harman |
collection | PubMed |
description | Healthcare price transparency is an effort to inform patient decision-making, but also to decrease prices and their variation across healthcare systems for equivalent medical services. The initiative is meaningful only for medical services that are shoppable—such as imaging examinations—for which patients incur out-of-pocket costs. Therefore, several countries in which patients commonly share a portion of their healthcare costs have been implementing mandates to improve healthcare price transparency. However, the provisional implementation has many issues, especially in the United States, including provider non-compliance and limited accessibility of price transparency tools by the general public. Many of the existing tools are not user-friendly, are difficult to navigate, focus on charges and health plan negotiated rates rather than patients’ out-of-pocket costs, and disclose prices on the service level instead of per episode of care. As such, the disclosed amounts are often not reliable. Many price transparency tools also lack valid and measurable quality metrics, which can result in a selection of high-cost care as a proxy for high-value care, as well as an increase in healthcare prices when providers want to imply they offer high-quality care. Nevertheless, the impact of the initiatives on patients’ decision-making and healthcare costs remains unclear. While transparency initiatives are patient-centric, efforts should be made to increase patient engagement, provide accurate patient-specific out-of-pocket cost information, compare available treatment and provider alternatives, and couple price information with quality metrics to enable making fully informed decisions. |
format | Online Article Text |
id | pubmed-10607402 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The British Institute of Radiology. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106074022023-10-28 Healthcare price transparency in North America and Europe Araich, Harman Tran, Julia Jung, Jinho Horný, Michal Sadigh, Gelareh Br J Radiol Review Article Healthcare price transparency is an effort to inform patient decision-making, but also to decrease prices and their variation across healthcare systems for equivalent medical services. The initiative is meaningful only for medical services that are shoppable—such as imaging examinations—for which patients incur out-of-pocket costs. Therefore, several countries in which patients commonly share a portion of their healthcare costs have been implementing mandates to improve healthcare price transparency. However, the provisional implementation has many issues, especially in the United States, including provider non-compliance and limited accessibility of price transparency tools by the general public. Many of the existing tools are not user-friendly, are difficult to navigate, focus on charges and health plan negotiated rates rather than patients’ out-of-pocket costs, and disclose prices on the service level instead of per episode of care. As such, the disclosed amounts are often not reliable. Many price transparency tools also lack valid and measurable quality metrics, which can result in a selection of high-cost care as a proxy for high-value care, as well as an increase in healthcare prices when providers want to imply they offer high-quality care. Nevertheless, the impact of the initiatives on patients’ decision-making and healthcare costs remains unclear. While transparency initiatives are patient-centric, efforts should be made to increase patient engagement, provide accurate patient-specific out-of-pocket cost information, compare available treatment and provider alternatives, and couple price information with quality metrics to enable making fully informed decisions. The British Institute of Radiology. 2023-11 2023-09-03 /pmc/articles/PMC10607402/ /pubmed/37660401 http://dx.doi.org/10.1259/bjr.20230236 Text en © 2023 The Authors. Published by the British Institute of Radiology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 Unported License http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial reuse, provided the original author and source are credited. |
spellingShingle | Review Article Araich, Harman Tran, Julia Jung, Jinho Horný, Michal Sadigh, Gelareh Healthcare price transparency in North America and Europe |
title | Healthcare price transparency in North America and Europe |
title_full | Healthcare price transparency in North America and Europe |
title_fullStr | Healthcare price transparency in North America and Europe |
title_full_unstemmed | Healthcare price transparency in North America and Europe |
title_short | Healthcare price transparency in North America and Europe |
title_sort | healthcare price transparency in north america and europe |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607402/ https://www.ncbi.nlm.nih.gov/pubmed/37660401 http://dx.doi.org/10.1259/bjr.20230236 |
work_keys_str_mv | AT araichharman healthcarepricetransparencyinnorthamericaandeurope AT tranjulia healthcarepricetransparencyinnorthamericaandeurope AT jungjinho healthcarepricetransparencyinnorthamericaandeurope AT hornymichal healthcarepricetransparencyinnorthamericaandeurope AT sadighgelareh healthcarepricetransparencyinnorthamericaandeurope |